




AMCP Publishes Resources on the 2024 Election and Impacts on Health Policy

This month, millions of Americans took to the polls to vote in local, state, and federal elections. And while the rush of the 2024 election season has largely subsided, the impact of these election results on health policy is just beginning to unravel. On Nov. 13, AMCP published a deck titled "2024 Election Impact: Health Care Policy under President Trump and in the 119th Congress." The deck highlights the expected health policy priorities of a second Trump administration, covering topics from Pharmacy Benefit Manager and 340B drug discount program reform, to an overhaul of the U.S. prescription drug patenting framework. The deck also covers anticipated shifts in policymaking around subjects such as Medicare drug price negotiation and Part D redesign, reproductive health care, and telehealth.

[View the 2024 Election Impact](#)



Lame Duck Congress Offers Opportunities to Expand VBAs in Medicaid

On Nov. 12, lawmakers returned to Washington, D.C. with a number of "must-pass" legislative priorities to wrap up before the next Congress is sworn in on Jan. 3. While many of these priorities, including the reauthorization of the National Defense Authorization Act and farm bill, aren't explicitly concerned with health policy, other pressing items such as the expiration of government funding on Dec. 20 offer opportunities to pass legislation that would benefit patients and managed care pharmacy professionals nationwide. One such bill is the Medicaid VBPs for Patients (MVP) Act ([H.R. 2666/S. 4204](#)), which would enhance Medicaid patient access to high-cost therapies by codifying the existing "multiple best price" rule. This rule allows manufacturers to report multiple best prices for drugs that are subject to value-based purchasing arrangements. The bill intends to expand the use of such arrangements within Medicaid programs, while also protecting these state programs from paying for high-cost treatments that are not effective. AMCP continues to urge Members of Congress to support this critical legislation.

[Call on your Members of Congress](#) to support the MVP Act during the lame duck session.

[Take Action](#)

Health Policy, Elections Top of Mind at AMCP Nexus 2024

Last month, thousands of managed care pharmacy professionals descended upon Las Vegas for [Nexus 2024](#). During the week, conversations on pharmacoeconomics and real-world evidence were heard throughout the MGM Grand Hotel and Convention



Center, but health policy and the upcoming presidential election remained top of mind. Nexus 2024 began on Monday, Oct. 14 with a four-hour preconference program on Medicare Part D redesign and Pharmacy Benefit Manager reforms, which was followed later in the week by Continuing Education (CE) sessions on Federal and State managed care legislation and regulations. Programming on Oct. 15 and 16 also included CE sessions on Medicare Part D redesign and trending GLP-1 weight loss drugs. Thursday, Oct. 17 capped off the end of the meeting with a keynote session on the 2024 election and its impacts on health policy.

[Access the Sessions](#)

AMCP Urges Support for the PREVENT HPV Cancers Act

Human papillomavirus (HPV) is a viral infection that can lead to the development of several types of cancer, including cervical cancer. Yet, the CDC finds that on-time HPV vaccination has the potential to prevent roughly 90% of HPV-associated cancers. On Oct. 28, AMCP joined dozens of members of the [HealthyWomen HPV Coalition](#) in a sign-on letter, urging Members of Congress to support the [PREVENT HPV Cancers Act \(H.R. 3633\)](#). The bill establishes a national education campaign to raise awareness about HPV and HPV-related cancers, while also providing funding for the federal Breast and Cervical Cancer Early Detection Program, extending activities to reduce cervical cancer mortality among uninsured and underserved patients. The undersigning organizations also urge Congress to normalize HPV vaccinations as a cancer prevention method, which could help alleviate avoidable HPV-related cancer diagnoses nationwide.

[Read the Full Sign-On Letter](#)

AMCP Members, Staff Make Health Policy Headlines at Nexus 2024

During Nexus 2024, AMCP and its members earned a significant amount of media buzz around the trending health policy topics discussed during the meeting. Adam Colborn, Associate Vice President of Congressional Affairs at AMCP, was featured in a three-part video interview with the [American Journal of Managed Care \(AJMC\)](#), where he discussed [the rise of GLP-1 receptor agonists](#), [health care-related aspects of the Inflation Reduction Act and their impacts on patients](#), as well as [legislation designed to improve reimbursement for and increase the uptake of Prescription Digital Therapeutics](#). Several AMCP members, including Kimberly Westrich, also [sat down with AJMC](#) to discuss the year's most pressing health policy challenges, as well as innovative solutions for addressing such challenges. Implementation of the Inflation Reduction Act was also top-of-mind for Nexus attendees, including Kelly Makay and Crescent Moore, consultants with BluePeak advisors, who touched on what to expect in 2025 and beyond with [First Report Managed Care](#) and [Managed Healthcare Executive](#).

[Read additional Nexus 2024 Media Coverage](#)

AMCP, 675 North Washington Street, Suite 220, Alexandria, VA 22314, United States.
[Manage Preferences](#)